Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype by Ramalho, Renata et al.
Neurokinin-1 receptor, a new modulator of lymphangiogenesis in
obese-asthma phenotype
Renata Ramalho, Joana Almeida, Rubén Fernandes, Raquel Costa, Ana Pirraco, Luísa Guardão,
Luís Delgado, André Moreira, Raquel Soares 
a b s t r a c t
Aim
th
NK
an
in
all
Ma
NK
pr
NK
Ke
VA
blo
th
in
Sig
ipo
tis
qu
ph
I
t
i
ﬂ
t
m
(
ls: Obesity and asthma are widely prevalent and associated disorders. Recent studies of our group revealed
at Substance P (SP) is involved in pathophysiology of obese-asthma phenotype in mice through its selective
1 receptor (NK1-R). Lymphangiogenesis is impaired in asthma and obesity, and SP activates contractile
d inﬂammatory pathways in lymphatics. Our aim was to study whether NK1-R expression was involved
lymphangiogenesis on visceral (VAT) and subcutaneous (SAT) adipose tissues and in the lungs, in obese-
ergen sensitized mice.
in methods:Diet-induced obese and ovalbumin (OVA)-sensitized Balb/c mice were treated with a selective
1-R antagonist (CJ 12,255, Pﬁzer Inc., USA) or placebo. Lymphatic structures (LYVE-1+) and NK1-R ex-
ession were analyzed by immunohistochemistry. A semi-quantitative score methodology was used for
1-R expression.
y ﬁndings: Obesity and allergen-sensitization together increased the number of LYVE-1+ lymphatics in
T and decreased it in SAT and lungs. NK1-R was mainly expressed on adipocyte membranes of VAT,
od vessel areas of SAT, and in lung epithelium. Obesity and allergen-sensitization combined increasedLymphangiogenesis
ntroduction
The lymphatic vascular system is critical 1-R antagonist treatment reversed the effects observed
accompanied by increased expression of NK1-R on ad-e expression of NK1-R in VAT, SAT and lungs. NK
lymphangiogenesis in those tissues.
niﬁcance: The obese-asthma phenotype in
se tissues and lung epithelium, reﬂectingKeywords:
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Asthma
Allergen-challenge
NK1-R
Substance P
LYVE-1
mice is
that SP released during inﬂammation may act directly on these
sues. Blocking NK1-R affects lymphangiogenesis, implying a role of SP, with opposite physiological conse-
ences in VAT, and in SAT and lungs. Our results provide a clue for a novel SP role in the obese-asthma
enotype.for reabsorption of ex-
lation. By transporting 
parameters (Detoraki et al., 2009; Wada et al., 2011), implying a 
strong association between lymphangiogenic process and adipose tis-
sue metabolism. Furthermore, lymphatic ﬂuid associates with fat de-
position, and lymphatic vascular defects may lead to adult-onset ravasated ﬂuid and dietary fat into the circu
nﬂammatory cells to lymphoid organs, it also plays a critical role in in- obesity (Lijnen et al., 2009).ammation, infection and immunity. In comparison to angiogenesis, On the other hand, asthma is a chronic inﬂammatory disease, 
where airway edema occurs whenever plasma leakage from blood he molecular mechanisms underlying lymphatic vessels develop-
vessels exceeds lymph vessels drainage capacity. Mast cells, macro-ent are less well characterized. Vascular endothelial growth factor 
VEGF)-C is a member of the VEGF family, mainly involved in 
ymphangiogenesis that closely correlates with metabolic and lipidphages and eosinophils, which migrate into the airways, are able to 
release huge amounts of angiogenic and lymphangiogenic growth fac-
tors, rendering these cells crucial promoters of lymphangiogenesis 
(Detoraki et al., 2010). Nevertheless, data regarding the distribution 
and role of lymphatic vessels in the lung during inﬂammatory condi-
tions remains rather scarce.
Obesity and asthma are widely prevalent and associated disor-
ders (Shore, 2006). Obesity is recognized as a risk factor for asthma
development in both children and adults (Beuther and Sutherland,
2007). Also, a distinct asthma phenotype has been identiﬁed in
obese subjects. This phenotype is characterized by increase asthma
severity, impaired glucocorticoid response, reduced response to
standard medication and metabolic and immune imbalances related
to the obese state (Lessard et al., 2008; Stream and Sutherland,
2012). Epidemiological studies reveal that the association between
obesity and asthma has been challenging for both researchers and
clinicians. Nevertheless, the mechanistic basis of this association re-
mains an open ﬁeld for investigation (Farah and Salome, 2012).
Substance P is a neuropeptide originally discovered in 1931 by Ulf
von Euler and John H. Gaddum (Devane, 2001), involved in neurogen-
ic inﬂammation by acting through its selective NK1 receptor (NK1-R)
(Datar et al., 2004). In addition to the previously recognized effects on
asthma (bronchonstrictor agent, inductor of mucus secretion, elicitor
of airway responsiveness, pro-inﬂammatory mediator) (Chu et al.,
2000; Groneberg et al., 2006) and obesity (orexigenic, weight gain
promoter) (Karagiannides et al., 2011; Karagiannides et al., 2008),
we recently studied SP as a potential mechanism behind the obese-
asthma phenotype. Accordingly, we showed that serum SP is in-
creased in obese allergen-sensitized mice (Ramalho et al., 2012) and
that targeting NK1-R with a selective antagonist (CJ 12,255) improves
both metabolic (weight gain, insulinemia, glycemia, and adipocyte
areas) and lung-related parameters (allergen sensitization and peri-
bronchial inﬂammation) in obese sensitized and allergen-challenged
mice (Ramalho et al., 2013).
Recent evidence indicates that neuropeptides such as SP strongly af-
fect lymphatic vessels contractility (Kurowska-Stolarska et al., 2011).
Although SP has been shown to bind to NK1 receptor in lymphatic en-
dothelial cells (Rayner and Van Helden, 1997), there is no information
concerning the role of this neuropeptide in lymphangiogenesis.
Given the previous established role of SP in diet-induced obesity
as well as in allergic asthma, and taking into account that lymph-
angiogenesis is relevant both during adipose tissue expansion and
in asthma, the aim of the present study was to examine the role of
SP in lymphangiogenesis, in the adipose tissue and lung of a diet-
induced and allergen-challenged mouse model.
Material and methods
Animals and study design
Balb/c mice aged 6–8 weeks old were used in this study. The mice
were purchased from Charles-River (USA) and kept in a controlled en-
vironment (temperature: 22–24 °C; humidity: 55%; air renovations/
hour: 15; light cycle (hour): 12/12) with ad libitum access to solid
food and water. Mice were randomly divided into 6 groups (6 inde-
pendent experiments, n = 6–8 per group). The control groups were
obese, lean, OVA-lean and OVA-obese. The two other groups were
NK1-R antagonist (CJ 12,255) treated mice: OVA-Lean + CJ and
OVA-obese + CJ. All in vivo manipulations were handled by trained
technicians and in agreement with the Portuguese Act 1005/92
(number 3, iii) and European Community guidelines (86/609/EEC)
for the use of experimental animals. This study was approved by the
Portuguese National Authority for Animal Health.
Mice in the “obese” groups were fed a high fat diet (45 kcal % fat,
4.73 kcal/g, Research Diets #D12451) for 17 weeks. “Lean” mice re-
ceived normal diet (11 kcal% fat w/corn starch, Research Diets
#D12328) for the same period. Final weight was lean 25.2 ± 0.98 g,
obese 30.0 ± 1.3 g, OVA-lean 25.3 ± 0.5 g, OVA-obese 30.5 ± 1.0 g,
OVA-lean + CJ 24.5 ± 1.4 g and OVA-obese + CJ 24.2 ± 1.5 g.
Animals were systemically sensitized by means of intraperitoneal
injections of 10 μg ovalbumin (OVA, #LS003048, Worthington, NJ,
USA) adsorbed to 1.5 mg of aluminumhydroxide Al(OH)3 (AlumImject,
Pierce, Rockford, IL, USA) as adjuvant on days 1, 14, and 21. Animals
received two consecutive local aerosol challenges of 1% OVA (inphosphate-buffered saline, PBS) for a period of 20 min on days 26 and
27 (2 × challenge). Challenge was repeated on days 33 and 34, prior
to mice sacriﬁce. Non-sensitized animals were treated with intraperito-
neal PBS and aerosol OVA (Ramalho et al., 2012).
To antagonize the NK1-R, we used the selective antagonist 6-
diphenylmethyl-5-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo
(2.2.2)octane-3-carboxylic acid, also known as CJ 12,255 (Pﬁzer Inc.,
Groton, CT, USA). One day after the last aerosol challenge, mice in the
“CJ” group received a daily intraperitoneal injection of 300 μg CJ
12,255, and control groups received saline solution, for 7 consecutive
days prior to sacriﬁce.
After sacriﬁce with intraperitoneal anesthetic overdose of sodium
pentobarbital 6 mg/ml, lungs and adipose tissues were removed,
ﬁxed with 4% paraformaldehyde and embedded in parafﬁn. Sections
of 4–5 μm from all tissues were stained with hematoxylin and eosin
and prepared for immunohistochemistry.
Immunohistochemistry of lymphatic vessels
To study lymphatic structures we selected LYVE-1, the hyaluronan
receptor in lymphatic endothelial cell (LECs) and a CD44 homologue.
Immunohistochemistry was performed with LYVE-1: ab33682 rabbit
anti-mouse polyclonal antibody (Abcam plc, Cambridge, UK) and in-
cubated with biotinylated goat anti-rabbit secondary antibody
IgG-B: sc-2040 (Santa Cruz Biotechnology, Inc., EUA). VECTASTAIN
Elite ABC Kit (Vector Laboratories, Inc., EUA) and 3,3′-diaminoben-
zidine (Abcam plc, UK) were used for signal ampliﬁcation. Control
blood vessels were stained with anti-mouse monoclonal antibody
CD31 (PECAM-1): 89C2 (Cell Signaling Technology, Inc., EUA) with
goat anti-rabbit IgG-B: sc-2040 (Santa Cruz Biotechnology, Inc.,
EUA). LYVE-1+ lymphatics were identiﬁed by presence of staining.
Areas without staining were considered as negative for lymphatics.
Number of LYVE-1+ lymphatic vessels was counted in 7–10 ran-
domly selected tissue sections per mouse.
Immunohistochemistry of NK1-R
Immunohistochemistry was performed using NK1-R rabbit anti-
mouse antibody (Novus Biologicals, LLC) and biotinylated goat
anti-rabbit secondary antibody. VECTASTAIN Elite ABC Kit (Vector
Laboratories, Inc., EUA) and 3,3′-diaminobenzidina (Abcam plc, UK)
were used for signal ampliﬁcation. We used a semi-quantitative
score methodology to quantify NK1-R expression. Percentage of
stained structures (P) was scored as 0 (b10%), 1 (10–15%), 2 (25–
50%), 3 (50–75%) or 4 (N75%). The score system for intensity (I) of
staining was 1 (weak staining), 2 (moderate staining) or 3 (strong
staining). The immunohistochemical score for NK1-R was obtained
by multiplying the percentage of stained structures by the intensity
(P × I = maximum 12). Areas without staining were considered as
negative for NK1-R.
In order to exclude false-positive or false-negative signals, the
speciﬁcity of primary and secondary antibodies were tested prior to
the experiment, and tissue preparation was performed with espe-
cial attention to ﬁxation conditions, temperature and duration of incu-
bation in primary antibody and secondary antibody solution, and
duration of the rinsing steps between antibody solutions. Negative
controls for the immunostaining were carried out by omission of the
primary antibody.
Statistical analysis
Data are presented as mean ± SEM, unless otherwise stated. All
tests were performed using Graphpad Prisma version 5.00 (Graphpad
Software, San Diego, CA, USA). Student's t-test and Mann–Whitney
U-test were used to analyze number of LYVE-1+ lymphatic vessels
and NK1-R expression, respectively. All groups were compared with
Analysis of Variance (ANOVA) with Bonferroni correction for multiple
comparisons.
Results
LECs density in VAT, SAT and lungs of obese and/or allergen sensitized
mice
We ﬁrst evaluated the density of LECs in the two adipose tissue
stores and lungs in obese and OVA-sensitized mice.
Both obesity and allergen-sensitization conditions increased the
number of LYVE-1+ lymphatics in VAT (Fig. 1, A: lean versus obese,
p = 0.025; obese versus OVA-obese, p = 0.049; and tendency in
OVA-lean). In addition, obesity further enhanced the number ofFig. 1. LYVE-1+ lymphatics inVAT. A—Number of LYVE-1+ lymphatics inVAT; animals per gro
LYVE-1 on VAT (LYVE-1+, 200×); B1, OVA-lean; B2, OVA-lean-CJ; B3, OVA-obese; B4, OVA-ob
cations are shown in right side insights.LYVE-1+ lymphatics induced by allergen sensitization in this tissue
(Fig. 1, A: OVA-lean versus OVA-obese, p = 0.038).
Strikingly, obesity and allergen-sensitization presented opposite
effect in the number of lymphatics in SAT. Obesity resulted in a signif-
icant reduction in the number of LECs. OVA-sensitized mice exhibited
also a decrease in LECs in leanmice and a tendency toward a reduction
in obese sensitized mice (Fig. 2, A: lean versus obese, p = 0.025; lean
versus OVA-lean, p b 0.001). The association of obesity and allergen-
sensitization led to a tendency for reduced number of LYVE-1+ lym-
phatics (Fig. 2, A).
Obesity and allergen-sensitization independently decreased the
number of LYVE-1+ lymphatics in lungs (3, A: lean versus obese,
p = 0.0255; lean versus OVA-lean, p = 0.0028; and obese versus
OVA-obese, p = 0.053). The association of obesity further reducedup 6–8; CJ indicates groups treatedwithNK1-R antagonist. B— Immunohistochemistry for
ese-CJ; photomicrographs presented are representative of the respective group. Magniﬁ-
Fig. 2. LYVE-1+ lymphatics in SAT. A—Number of LYVE-1+ lymphatics in SAT; animals per group 6–8; CJ indicates groups treatedwith NK1-R antagonist. B— Immunohistochemistry for
LYVE-1 on SAT (LYVE-1+, 200×); B1, OVA-lean; B2, OVA-lean-CJ; B3, OVA-obese; B4, OVA-obese-CJ; photomicrographs presented are representative of the respective group. Magniﬁ-
cations are shown in right side insights.the number of LYVE-1+ lymphatics present in the lungs of allergen
sensitized mice (Fig. 3, A: OVA-lean versus OVA-obese, p = 0.052).
Number of LYVE-1+ LECs were different among the groups
(VAT: p b 0.0001, R2 = 0.099; SAT: p b 0.0001, R2 = 0.123; lungs:
p b 0.0001, R2 = 0.215).
Expression of NK1-R on VAT, SAT and lungs
To examine whether SP played any role in the observed changes in
the number of LECs upon obesity or allergen sensitization, we next
examined its receptor expression in the different tissues.
Immunohistochemical analysis of VAT showed that NK1-R was
mainly expressed on adipocyte membranes throughout the tissue
(Fig. 4, B). Both obesity and allergen-sensitization increased expression
of NK1-R (Fig. 4 A, lean versus obese, p = 0.023; lean versus OVA-lean,
p = 0.002; obese versusOVA-obese, p = 0.0091). Interestingly, obesityenhanced NK1R expression induced by allergen sensitization (Fig. 4 A,
OVA-lean versus OVA-obese, p = 0.059), implying an additive effect
between both conditions.
In SAT NK1-R expression was restricted to blood vessel areas
(Fig. 5, B). In this tissue, allergen-sensitization increased NK1-R ex-
pression both in lean and in obese-sensitized mice (Fig. 5, A: lean
versus OVA-lean, p b 0.001; obese versus OVA-obese, p b 0.001), but
obesity per se did not affect this expression. Nevertheless, obesity
and allergen-sensitization combined resulted in increased NK1-R ex-
pression in SAT (Fig. 5, A: OVA-lean versus OVA-obese, p = 0.015).
NK1-R was also expressed in lungs, mainly in lung epithelium and
predominantly upon allergen-sensitization (Fig. 6, B; Fig. 1, A: lean
versus OVA-lean, p b 0.001; obese versus OVA-obese, p b 0.001). Obe-
sity per se did not affect NK1-R expression on lung epithelium (Fig. 6,
B3), but it rendered this tissue much more detached and disorganized
in obesemice, indicating that obesity negatively affected lung structures.
Fig. 3. LYVE-1+ lymphatics in lungs. A—Number of LYVE-1+ lymphatics in lungs; animals per group 6–8; CJ indicates groups treatedwithNK1-R antagonist. B— Immunohistochemistry
for LYVE-1 in lungs (LYVE-1+, 200×); B1, OVA-lean; B2, OVA-lean-CJ; B3, OVA-obese; B4, OVA-obese-CJ; photomicrographs presented are representative of the respective group. Mag-
niﬁcations are shown in right side insights.Interestingly, allergen-sensitization led to NK1-R overexpression in lung
epithelium of obese mice when compared to lean ones (Fig. 6, A:
OVA-lean versus OVA-obese, p = 0.015), indicating a synergistic effect
between the two conditions in SP signaling.
We then conﬁrmed these ﬁndings by treating mice with NK1-R
antagonist. As expected, blocking NK1-R resulted in decreased expres-
sion of NK1-R in VAT (Fig. 4, A: OVA-obese versus OVA-obese + CJ,
p = 0.0385; OVA-lean versus OVA-lean + CJ, p = 0.022), SAT
(Fig. 5, A: OVA-obese versus OVA-obese + CJ, p b 0.001; OVA-lean
versus OVA-lean + CJ, p = 0.002) and lung epithelium (Fig. 6, A:
OVA-obese versus OVA-obese + CJ, p = 0.013; OVA-lean versus
OVA-lean + CJ, p = 0.002) of OVA-obese or OVA-lean treated mice.
Remarkably, in contrast to VAT and SAT, the use of NK1-R antagonist
did not decrease NK1-R expression in lung epithelium to normal
(non-sensitized) levels either in lean or in obese mice (Fig. 6, A).Expression of NK1-R was different among the groups tested
(VAT: p b 0.0001, R2 = 0.427; SAT: p b 0.0001, R2 = 0.699; lungs:
p b 0.0001, R2 = 0.475).
Role of NK1-R signaling in lymphangiogenesis
When NK1-R was abrogated using NK1-R antagonist, a signiﬁcant
decrease in LYVE-1+ lymphatics was observed in VAT from both
OVA-obese and OVA-lean treated mice to levels identical to the ones
observed in untreated mice (Fig. 1B2 and B4; Fig. 1A: OVA-obese
versus OVA-obese + CJ, p = 0.026; OVA-lean versus OVA-lean + CJ,
p = 0.017). In SAT, treated mice showed increased number of
LYVE-1+ lymphatics to normal (non-sensitized) levels (Fig. 2B2 and
B4; Fig. 2A: OVA-obese versus OVA-obese + CJ, p b 0.001; OVA-lean
versus OVA-lean + CJ, p = 0.015). Identical ﬁndings were observed
Fig. 4. NK1-Rexpression on VAT. A— Immunohistochemical score for NK1-Ron VAT; animals per group6–8; CJ indicates groups treatedwithNK1-R antagonist. B— Immunohistochemistry
for NK1-RonVAT (NK1-R+, 200×); B1, lean; B2, OVA-lean; B3, obese; B4, OVA-obese; photomicrographs presented are representative of the respective group.Magniﬁcations are shown in
right side insights.in the lungs, where NK1-R antagonist also reversed the number of
LYVE-1+ lymphatics towards non-sensitized levels (Fig. 3B2 and B4;
Fig. 3A: OVA-lean versus OVA-lean + CJ, p = 0.0036; OVA-obese
versus OVA-obese + CJ, p = 0.0447). These ﬁndings imply that
lymphangiogenesis depends on SP signaling pathway.
Discussion
To our knowledge, this is the ﬁrst study to demonstrate that
lymphangiogenesis is effectively imbalanced in visceral and subcuta-
neous adipose tissue depositions, as well as in lungs of obese-allergen
challenged mice in comparison to lean nonsensitized ones. We were
further able to show that this lymphangiogenesis imbalance depends
on the expression of SP speciﬁc receptor, NK1-R.
As the remaining members of this tachykinin family of neuropep-
tides (neurokinin A — NKA, and neurokinin B — NKB), SP exerts its
biological effects by activating speciﬁc receptors (Datar et al., 2004).NK1-R exhibits higher afﬁnity for SP than any other tachykinin,
being thus considered a selective receptor for SP (Datar et al., 2004;
Douglas and Leeman, 2011). NK1-R was found in several structures
of central nervous system, in peripheral nervous system (urinary
bladder, salivary glands, small and large bowels), peripheral tissues
(vascular endothelium, epithelium of bronchi and bronchioles and
endothelium of bronchial microvessels, smooth muscle layers, sub-
mucosa and intestinal epithelium) and immune cells (lymphocytes,
macrophages) (Quartara and Maggi, 1998). This widespread distribu-
tion of NK1-R reﬂects the variety of SP biological functions (Douglas
and Leeman, 2011; Quartara and Maggi, 1998). Along with the recog-
nition of its role in central nervous system as a pain neurotransmitter,
SP has also been implicated in respiratory diseases, gut inﬂamma-
tion, obesity and diabetes (Chu et al., 2000; Datar et al., 2004;
Karagiannides et al., 2011; Karagiannides et al., 2008). We have previ-
ously demonstrated that obesity and allergen challenge independent-
ly increased serum SP, and the presence of both obesity and asthma
Fig. 5. NK1-R expression on SAT. A— Immunohistochemical score for NK1-R on SAT; animals per group 6–8; CJ indicates groups treatedwith NK1-R antagonist. B— Immunohistochemistry
for NK1-R on SAT (NK1-R+, 200×); B1, lean; B2, OVA-lean; B3, obese; B4, OVA-obese; photomicrographs presented are representative of the respective group.Magniﬁcations are shown in
right side insights.further increased these levels (Ramalho et al., 2012). Further, we ob-
served a positive effect of a selective NK1-R antagonist on metabolic
and allergen inﬂammatory parameters on the obese-asthma pheno-
type in mice (Ramalho et al., 2013). In the current study, we showed
that NK1-R is expressed throughout VAT, in close vicinity to blood ves-
sels in SAT and in lung epithelium, and this expression is increased in
our mice model of obesity and asthma. The interaction between SP
and NK1-R leads to the activation of NF-κB that enhances proinﬂam-
matory cytokines release, such as IL-1, IL-6, TNF-α, MIP-1β and
IFN-γ, which are closely related to inﬂammatory conditions like obesi-
ty and asthma (Quartara and Maggi, 1997). This low grade inﬂamma-
tion is particularly associated with VAT rather than SAT, which
explains the different NK1-R expressions observed between the two
adipose tissue depots.
Another striking ﬁnding is the fact that lymphangiogenesis was in-
creased in obesity and allergen challenge in VAT, but reduced in SAT.These ﬁndings were further exacerbated when obesity and allergen-
sensitization and challenge were considered together, both in VAT
and in SAT. Lymphatic vessels are physically associated with adipose
tissue. VAT surrounds the collecting lymphatic vessels of mesentery
and of intra-abdominal lymph nodes (Chakraborty et al., 2010;
Harvey, 2008). Conversely, SAT is more closely associated to dermal
lymphatic vasculature (Harvey, 2008). It has been previously reported
that inﬂammation produced in the obese may promote lymphan-
giogenesis within VAT (Harvey, 2008; Schneider et al., 2005). Neo-
lymphangiogenesis and leakage of lymphatic ﬂuid from ruptured
lymphatic vessels accompanies adipose tissue expansion and contrib-
utes to extension of inﬂammation (Chakraborty et al., 2010). These
ﬁndings corroborate the different roles of these two adipose tissue de-
pots. Furthermore, the use of NK1-R antagonist reversed lymphangio-
genic effects in VAT, in SAT, and in lungs, implying a signiﬁcant role of
SP speciﬁc receptor in lymphangiogenesis. In agreement with these
Fig. 6.NK1-R expression on lungs. A— Immunohistochemical score forNK1-R on lungs; animalsper group6–8; CJ indicates groups treatedwithNK1-R antagonist. B— Immunohistochemistry
for NK1-R on lungs (NK1-R+, 200×); B1, lean; B2, OVA-lean; B3, obese; B4, OVA-obese; photomicrographs presented are representative of the respective group.Magniﬁcations are shown in
right side insights.ﬁndings, previous studies from the literature reveal that SP modulates
lymphatic contractility and contributes to chronic inﬂammation
(Chakraborty et al., 2010; Kurowska-Stolarska et al., 2011).
In the lung, lymphatic system enables the clearance of edematous
ﬂuid (El-Chemaly et al., 2008). Impairment of lymphangiogenesis has
also been considered to be implicated in asthma pathogenesis. In fact,
recent data points to the lymphatic system as an important player in
decreasing airway wall remodeling in asthma (Detoraki et al., 2010).
Also, distribution of airway lymphatics was reported to be decreased
in fatal asthma, and disruption of lymphatics with accelerated muco-
sal edema was also observed (Ebina, 2008). In our study the obese-
asthma phenotype increased lymphangiogenesis in VAT, and de-
creased it in SAT and in lungs.
It is known that dysfunctional lymphatic vessels can cause pathol-
ogy as well as normal lymphatics can exacerbate pathology (Jonesand Min, 2011). In this scenario, different roles played by lymphatics
in different tissues can be explained by their tissue-speciﬁc function-
ality; and their role in pathology may be explained by their degree of
dysfunction. Increased number of lymphatics in VAT of obese-asthma
mice model can be explained by increased lymphangiogenesis due to
inﬂammation, a process in which VAT plays a major role. Also, the rel-
evance of lymphatics in fat deposition recently studied by Harvey et
al., suggests that lymph leakage may increase lipid storage in adipo-
cytes causing hypertrophy (Harvey, 2008). Additionally, lymphatic
vasculature has been recently reported to be involved in the reverse
cholesterol (RCT) in mice (Martel et al., 2013). In their study, Martel
C et al., demonstrated that the magnitude of inhibited RCT seems to
be correlated with the extent to which lymphatic vessels are absent
in skin surrounding the site were cholesterol-loaded macrophages
are injected, and that clearance of RCT from the arterial intima relies
on lymphatic vessels. This may explain why number of lymphatics in
SAT was reduced in these mice as compared to controls in our study
(Martel, Li, 2013).
Our results may somehow reﬂect the increased severity of the
obese-asthmaphenotype, as a chronic pro-inﬂammatory condition dur-
ing obesity may result in neo-lymphangiogenesis in VAT; on the other
hand, airway inﬂammation may induce impaired lymphangiogenesis,
reduced number of lymphatics, accumulation of extravasated ﬂuid,
and airway remodeling with persistent airﬂow obstruction.
Although immunohistochemistry enables the correct localization
of LECs and NK-1R expression, it is limited for quantiﬁcation pur-
poses; however our results were strengthened by the use of a semi-
quantiﬁcation methodology that is reliable and broadly used in the
majority of publications. This analysis is based on the intensity of
staining and the number of cells stained; and the investigator respon-
sible for the semi-quantiﬁcation was always blinded to the study.
Conclusions
Altogether, our ﬁndings support the hypothesis that acting upon
its speciﬁc receptor, NK1-R, in adipocytes or pulmonary epithelial
cells, SP is able to inﬂuence lymphangiogenesis, which plays a crucial
role in the obese-asthma phenotype, a disorder with increasing prev-
alence and incidence worldwide. Elucidating the molecular mecha-
nisms triggered by NK-1R-SP signaling is mandatory in order to
evaluate its putative effect as a novel therapeutic approach targeting
this obese-asthma phenotype.
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